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Introduction
Breast cancer detection and staging are constantly evolving
as technologies improve. Breast cancer surgery is also
undergoing continuous refinement, with the objective being
to achieve optimal cosmetic results. Surgery has been
combined with intraoperative radiation therapy to achieve the
best local disease control with minimal side effects.
Presentations at the Conference focused on recent
advances in techniques for sentinel node biopsy (SNB).
Patient preferences are an essential component of treatment
decision making, leading to improved quality of life and
patient satisfaction. The response to preoperative systemic
treatment can be used to tailor treatment to individual
patients. Finally, there is a need to identify the optimal
sequence of endocrine therapies in the adjuvant setting.
Researchers and clinicians at the Milan meeting have
made important contributions to advances in medical
therapies. This meeting report provides a brief
presentation on some of these developments, with the
objective being to stimulate ideas regarding what should
be done tomorrow.
Regional lymph node mapping
Monica Morrow (Northwestern Memorial Hospital,
Chicago, IL, USA) presented indications and contra-
indications to SNB. She observed that clinical experience
with lymphatic mapping and SNB has defined populations
in which the technique is likely to be safe and accurate. At
the consensus conference in 2001, contraindications to
SNB were reported to be clinically positive lymph nodes;
locally advanced breast cancer, before or after
neoadjuvant therapy; pregnancy or lactation; and prior
axillary surgery [1]. Since that time data have been
reported that indicate that SNB can be performed after
neoadjuvant therapy in patients without locally advanced
breast cancer, and that the technique is appropriate for
those with multicentric carcinoma [2]. Similar findings
regarding the accuracy of axillary SNB after neoadjuvant
chemotherapy were presented by Schwartz (The Breast
Health Institute, Philadelphia, PA, USA). In fact, Schwartz
and colleagues have abandoned complete (levels I and II)
axillary dissection in patients undergoing induction
chemotherapy whose axillae are considered clinically
negative following their chemotherapy, irrespective of
node status prior to neoadjuvant treatment. Morrow
discussed concerns regarding the clinical implications of a
false-negative SNB. This issue was addressed with the
publication of follow-up data on 4551 patients who
underwent SNB alone, with only five (0.001%) isolated
axillary recurrences. Randomized trials have demonstrated
that morbidity after SNB is significantly less than after
axillary dissection, both in the immediate postoperative
period and during 2 years of follow up.
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Abstract
The 6th Milan Breast Cancer Conference, held in Milan, Italy, over 16–18 June 2004, was attended by
more than 1000 physicians from 60 countries. This report summarizes the highlights of the most
interesting conference presentations on selected topics.
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Umberto Veronesi (European Institute of Oncology,
Milano, Italy) reported on the first series (376 patients) in
which the first node draining the tumour area was
identified in 99% with the use of a radiotracer (99Tc) and
gamma detector during surgery. All patients underwent
complete axillary dissection. The study found an overall
accuracy of 96.8%, a sensitivity of 93.3% and a specificity
of 100%. Veronesi also updated the findings of the Milano
trial on axillary SNB. Between 1998 and 1999, 516 patients
were randomized in a controlled study comparing SNB and
immediate axillary dissection versus SNB and dissection
only in those cases with a positive SNB. The average follow
up in the study is 5 years, and there are no differences
between the two arms of the study in local or axillary
recurrences, distant metastases and overall survival [3].
Since 1999, SNB has been offered as a standard of care
to all European Institute of Oncology breast cancer
patients. More than 7000 women underwent SNB, and
recent data revealed that there were fewer local
recurrence than expected. Armando Giuliano (John
Wayne Cancer Institute, Santa Monica, CA, USA)
discussed the current status of sentinel node dissection in
the USA. He observed that SNB had already become the
preferred management option for patients with clinically
negative lymph nodes at most breast cancer centres in the
country. The procedure was rapidly accepted because it is
a diagnostic procedure with high positive and negative
predictive values, and low morbidity. Currently, patients
with early breast cancer who are clinically node negative
are managed with SNB; also, in most centres, if the
sentinel node is tumour free, then axillary lymph node
dissection is not performed.
From the discussion, several factors were associated with
failure to identify a sentinel node: surgeon inexperience,
older age and obesity. Other than surgeon inexperience,
no factor has been identified that reliably predicts the
likelihood of a false-negative sentinel node.
Viviana Galimberti (European institute of Oncology,
Milano, Italy) reported that micrometastases (<2 mm) are
found more frequently by extensive pathological
examination of the sentinel node. In order to evaluate the
requirement for axillary surgery, patients with breast
cancer up to 3 cm with clinically negative axillae and found
by SNB to have only micrometastases were recruited and
randomly assigned either to complete axillary dissection or
to no further axillary treatment. The primary end-point of
the trial is disease-free survival. Thus far, about 250
patients have been recruited.
On aggregate, the data discussed in this session of the
meeting indicated that SNB is the preferred technique for
axillary staging in the majority of patients with stage I and II
breast cancer.
Partial breast irradiation
One of the ‘hot topics’ of the meeting was covered by the
session on partial irradiation of the breast [4]. From the
panel, the message was clear that, over the past decade,
breast conserving therapy (BCT) has become an
important option for patients with breast cancer; this is
because long-term disease free and overall survival rates
for BCT and radical surgery are similar. The current
standard of care for early operable breast cancer is
quadrantectomy or lumpectomy and a 5- to 7-week course
of whole-breast postoperative radiotherapy (RT). It is
possible to reduce treatment time by confining RT to the
tumour bed. Based on the hypothesis that it is sufficient to
just treat the index quadrant with RT, Roberto Orecchia
(European Institute of Oncology, Milano, Italy) described a
new technique for intraoperative RT using a single dose of
radiation delivered directly to the tumour bed. A mobile
linear accelerator with a robotic arm is utilized that delivers
an electron beam to produce energy ranging from 3 to
9 MeV. A single dose of 21 Gy was demonstrated to be
equivalent to 60 Gy delivered in 30 fractions at
2 Gy/fraction. Through a perspex applicator, radiation is
delivered directly to the mammary gland in order to spare
the skin. To protect the thoracic wall, an aluminium–lead
disc is placed between the gland and the pectoralis
muscle [5]. More than 600 patients have been randomized
into a trial comparing this new technique (electron
intraoperative therapy) with standard external RT. At this
time there is no statistically significant difference in local
relapse rates between the two arms.
Another randomized study was also presented by Jayant
Vajdya (University College London, London, UK), who
tested single dose treatment using low energy X rays
(Intrabeam™; Photoelectron Corporation, Lexington, MA,
USA) targeted at peritumoural tissues from within the
breast. The technique employs a miniature electron-beam
driven X-ray source that emits ‘soft’ X rays (50 kV). Rapid
attenuation of radiation within tissues occurs, and so the
dose is inversely proportional to the third power of the
distance between target and source, thus reducing the
damage to surrounding normal tissues and minimizing the
need for radiation protection for operating personnel. In
patients with small breast cancers, this could be the sole
treatment. A randomized trial (Targeted Intraoperative
Radiotherapy; TARGIT) is under way in the UK, Europe,
USA and Australia. Preliminary results indicate that this
technique has the potential to reduce local recurrence by
avoiding geographical misses and achieving excellent
dosimetry, replacing 6 weeks of postoperative RT in those
patients who are at low risk for local recurrence.
Roberto Gennari (European Institute of Oncology, Milano,
Italy) presented data on a new breast treatment device
(Mammosite RTS™; Proxima Therapeutics Inc., Alpharetta,
GA, USA) that was recently developed [6]. This devicedelivers a high-dose-rate source at the centre of an
inflatable balloon that is placed in the surgical cavity at the
time of BCT. This new device consists of a catheter with a
silicone balloon and a shaft approximately 6 mm in
diameter and 15 cm in length. The shaft contains a small
inflation channel and a larger central ‘treatment’ channel
for passage of the high-dose-rate source. An injection port
is attached to the inflation channel, and a Luer fitting is
attached to the treatment channel. An adapter is provided
separately that permits connection with any type of after-
loading device. A dose of 34 Gy is delivered at a depth of
1–2 cm from the surface of the balloon in 3.4 Gy fractions
(twice daily) over 5 days. More than 1500 devices have
been implanted worldwide, and the data indicate that
placement of the device is safe and easy to achieve after
brief surgical training, with excellent cosmetic results [7].
Giovanni Paganelli (European Institute of Oncology,
Milano, Italy) presented preliminary data on a new
technique termed the IART (intraoperative avidination for
radionuclide therapy) procedure. This procedure consists
of a first step in which the surgeon intraoperatively injects
avidin directly into the tumour bed; this is followed,
1–2 days later, by a second step in which 90Y/177Lu
radiolabelled biotin is intravenously injected. Avidin will
also percolate the tissue of the index quadrant and is
drained by locoregional lymph nodes, including the
internal mammary chain and upper clavicular. Avidin is not
expressed in normal tissues. Because of its positive
electric charge and the inflammatory reaction that occurs
after surgery, avidin is retained for several days at the site
of surgery and provides an ‘artificial receptor’ that binds
intravenous radioactive biotin with a very high affinity (kd
10–15) only at the surgical site.
News on adjuvant and neoadjuvant systemic
treatment
This session focused on the importance of tailoring systemic
treatments, taking into consideration all possible information
on primary cancer as well as patient preferences.
Richard Gelber (Dana Farber Cancer Institute, Boston,
MA, USA) indicated that disease and patient
characteristics should be evaluated to predict treatment
responsiveness. Nolè (European Institute of Oncology,
Milano, Italy) indicated that the future direction of
chemotherapy should be toward identifying the most
tolerable and effective chemotherapy regimens. Looking
for new chemotherapy regimens, he highlighted the
following objectives: to identify regimens that have fewer
subjective toxic effects, including gastrointestinal
symptoms and alopecia; to identify regimens that are
effective even in heavily pretreated patients, so that
significant palliation can be achieved; to identify effective
oral drugs; and to combine cytotoxics with endocrine
agents and monoclonal antibodies.
Marco Colleoni (European Institute of Oncology, Milano,
Italy) addressed the issue of primary endocrine therapy
and chemotherapy. He showed that primary endocrine
therapy can have high efficacy with a relatively favourable
side-effect profile in selected populations. Preoperative
endocrine therapy may permit early identification of
tumours that are resistant to endocrine therapy that
require alternative treatment, and has the potential
additional advantage that it can be continued throughout
the perioperative period.
Data from the literature indicate that, in patients with an
oestrogen receptor-positive tumour, a response rate of
50–70% can be achieved in approximately 3–4 months
using traditional endocrine manipulation, for example
administration of tamoxifen or new agents such as
aromatase inhibitors. Complete pathological remission is
achieved in fewer than 10% of the patients. Chemo-
therapy remains the mainstay of treatment, being
considered a more active and better documented option,
with objective remission achieved in 70–90% and
pathological remission in 15–30% of patients. Higher
pathological response rates can be achieved in patients
with endocrine unresponsive disease.
Optimal integration of endocrine therapy with
chemotherapy in patients with endocrine responsive
tumours should be further studied in the laboratory and in
clinical trials. In particular, the introduction of aromatase
inhibitors and gonadotropin-releasing hormone analogues,
administered in combination with chemotherapy, might
improve therapeutic results.
In the closing remarks, Carsten Rose (Lund University
Hospital, Lund, Sweden) discussed values and limitations
of systemic treatments. Recent findings were presented
that suggest that the risk for dying from breast cancer in
the European Community has fallen by 5% over the period
from 1985 to 2000. However, despite increasing use of
tamoxifen and chemotherapy in breast cancer, absolute
improvements in cure rates are minimal, and at present the
new pharmacological therapies can only account for a
small proportion of these cures.
Examples of new therapies are endocrine therapy with
third-generation aromatase inhibitors, cytotoxic therapy
with taxanes, and targeted therapies with monoclonal
antibodies such as trastuzumab and the novel
bisphosphonates. These therapies are more efficacious
than older forms of therapy. However, the estimated
clinical value of many of these new therapies is based on
data from small randomized studies, with questionable
designs and control treatments, and inadequate
estimations of long-term safety and toxicity. In addition, the
cost of these new anticancer drugs is several times
greater than that of older drugs.
Available online http://breast-cancer-research.com/content/7/1/E1Conclusion
New insights into prevention and discovery of markers of
therapy outcome and, in broad terms, development of
more sophisticated education tools and improvements in
communication skills both for patients and professionals
must be applied if further progress in our fight against
cancer is to be realized.
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